Climb Bio Inc (CLYM)Healthcare | Biotechnology | Wellesley Hills, United States | NasdaqGM
14.57 USD
-0.49
(-3.254%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 14.40 -0.17 (-0.168%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:12 a.m. EDT
The immediate outlook is bullish driven by a confluence of catalysts: a $110M private placement provides essential liquidity, institutional backing from FMR LLC adds credibility, and the addition to the Russell 2000 index offers a mechanical floor for the share price. The recent price action confirms this sentiment, with the stock surging from roughly $12.50 to $17.30 in under two weeks, breaking above key moving averages. However, the long-term picture remains precarious; the company is burning cash at a rapid rate with negative free cash flow and no dividend history, relying entirely on future drug readouts for survival. While the balance sheet is currently fortified by the new financing, the lack of profitability and the high-risk nature of biotech development mean this is a speculative play on near-term events rather than a stable investment. The options market is screaming for volatility, betting big on a move higher while hedging heavily against a failure of the upcoming clinical data. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.075029 |
| AutoARIMA | 0.092108 |
| MSTL | 0.094830 |
| AutoETS | 0.098429 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 16.58 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.381 |
| Excess Kurtosis | -0.44 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.549 |
| Market Cap | 836,846,208 |
| Forward P/E | -13.82 |
| Beta | 0.08 |
| Website | https://climbbio.com |
As of Aug. 22, 2026, 4:12 a.m. EDT: Speculators are positioning aggressively for a near-term rally, evidenced by massive open interest in out-of-the-money calls (strikes 20 and 22.5) relative to volume, suggesting a bet on a significant gap up. Conversely, deep out-of-the-money puts show heavy open interest, indicating a hedge against a crash or a contrarian view that the rally is a trap. Implied volatility is extremely skewed, with ATM put IV at 7.4 versus 1.31 for calls, reflecting a market pricing in a binary event where downside protection is far more expensive than upside speculation.
| Attribute | Value |
|---|---|
| 52 Week Change | 5.753363 |
| Address1 | 20 William Street |
| Address2 | Suite 145 |
| All Time High | 29.69 |
| All Time Low | 1.05 |
| Ask | 16.06 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,399,610 |
| Average Daily Volume3 Month | 1,365,408 |
| Average Volume | 1,365,408 |
| Average Volume10Days | 1,399,610 |
| Beta | 0.084 |
| Bid | 9.05 |
| Bid Size | 2 |
| Book Value | 4.171 |
| City | Wellesley Hills |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.57 |
| Current Ratio | 31.452 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 15.1192 |
| Day Low | 14.38 |
| Debt To Equity | 0.549 |
| Display Name | Climb Bio |
| Earnings Timestamp End | 1,755,174,600 |
| Earnings Timestamp Start | 1,755,174,600 |
| Ebitda | -64,628,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.136 |
| Enterprise Value | 655,037,248 |
| Eps Current Year | -0.77875 |
| Eps Forward | -1.05444 |
| Eps Trailing Twelve Months | -0.82 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.7246 |
| Fifty Day Average Change | 0.84539986 |
| Fifty Day Average Change Percent | 0.061597414 |
| Fifty Two Week Change Percent | 575.3363 |
| Fifty Two Week High | 18.33 |
| Fifty Two Week High Change | -3.7600002 |
| Fifty Two Week High Change Percent | -0.20512822 |
| Fifty Two Week Low | 1.54 |
| Fifty Two Week Low Change | 13.03 |
| Fifty Two Week Low Change Percent | 8.461039 |
| Fifty Two Week Range | 1.54 - 18.33 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,628,602,200,000 |
| Float Shares | 41,603,951 |
| Forward Eps | -1.05444 |
| Forward P E | -13.81776 |
| Free Cashflow | -33,989,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 28 |
| Fullday Change | -0.490001 |
| Fullday Change Percent | -3.25366 |
| Fullday Price | 14.4019 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00373 |
| Held Percent Institutions | 1.05233 |
| Implied Shares Outstanding | 57,436,255 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts. |
| Long Name | Climb Bio Inc |
| Market | us_market |
| Market Cap | 836,846,208 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_603195850 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -57,624,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 864,990,000 |
| Number Of Analyst Opinions | 14 |
| Open | 14.86 |
| Operating Cashflow | -52,699,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 866 857 2596 |
| Post Market Change | -0.1680994 |
| Post Market Change Percent | -1.1537365 |
| Post Market Price | 14.4019 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 15.06 |
| Price Eps Current Year | -18.70947 |
| Price Hint | 2 |
| Price To Book | 3.493167 |
| Profit Margins | 0.0 |
| Quick Ratio | 30.86 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | -0.490001 |
| Regular Market Change Percent | -3.25366 |
| Regular Market Day High | 15.1192 |
| Regular Market Day Low | 14.38 |
| Regular Market Day Range | 14.38 - 15.1192 |
| Regular Market Open | 14.86 |
| Regular Market Previous Close | 15.06 |
| Regular Market Price | 14.57 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 840,019 |
| Return On Assets | -0.18452999 |
| Return On Equity | -0.27097 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 57,436,255 |
| Shares Percent Shares Out | 0.13159999 |
| Shares Short | 7,557,264 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 6,871,210 |
| Short Name | Climb Bio, Inc. |
| Short Percent Of Float | 0.1856 |
| Short Ratio | 6.81 |
| Source Interval | 15 |
| State | MA |
| Symbol | CLYM |
| Target High Price | 35.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 22.85714 |
| Target Median Price | 22.0 |
| Total Cash | 183,123,008 |
| Total Cash Per Share | 3.188 |
| Total Debt | 1,314,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.82 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.324125 |
| Two Hundred Day Average Change | 6.2458744 |
| Two Hundred Day Average Change Percent | 0.750334 |
| Type Disp | Equity |
| Volume | 840,019 |
| Website | https://climbbio.com |
| Zip | 2,481 |